Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) Return on Equity (2022 - 2025)

Zentalis Pharmaceuticals has reported Return on Equity over the past 4 years, most recently at 0.58% for Q4 2025.

  • Quarterly results put Return on Equity at 0.58% for Q4 2025, down 10.0% from a year ago — trailing twelve months through Dec 2025 was 0.58% (down 10.0% YoY), and the annual figure for FY2025 was 0.5%, down 7.0%.
  • Return on Equity for Q4 2025 was 0.58% at Zentalis Pharmaceuticals, down from 0.57% in the prior quarter.
  • Over the last five years, Return on Equity for ZNTL hit a ceiling of 0.46% in Q1 2024 and a floor of 0.71% in Q1 2025.
  • Median Return on Equity over the past 4 years was 0.55% (2023), compared with a mean of 0.54%.
  • Biggest five-year swings in Return on Equity: rose 12bps in 2024 and later fell -25bps in 2025.
  • Zentalis Pharmaceuticals' Return on Equity stood at 0.51% in 2022, then fell by -17bps to 0.6% in 2023, then grew by 20bps to 0.48% in 2024, then decreased by -22bps to 0.58% in 2025.
  • The last three reported values for Return on Equity were 0.58% (Q4 2025), 0.57% (Q3 2025), and 0.57% (Q2 2025) per Business Quant data.